An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-Doses to Patients With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2017
At a glance
- Drugs THR 317 (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors BioInvent International
- 24 Jan 2012 Results have been published in the British Journal of Cancer.
- 17 Nov 2009 Results were presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
- 17 Nov 2009 Status changed from active, no longer recruiting to completed, according to a ThromboGenics media release.